This an open-label phase Ⅳ clinical trial of live attenuated varicella vaccine manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.The purpose of this study is to evaluate the immunity persistence of live attenuated varicella vaccine at 6 and 10 years after booster dose.
A total of 792 subjects aged 2 to 6 years including in per-protocol set (PPS) of immunogenicity assessment from previous phase Ⅲ clinical trial were enrolled. About 3.0ml of venous blood was collected at 6 and 10 years after booster immunization for antibody detection.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
PREVENTION
Masking
NONE
Enrollment
414
lyophilized powder, subcutaneous injection
Henan Provincial Center for Disease Control and Prevention
Zhengzhou, Henan, China
Seropositive rate
The seropositive rate of varicella-zoster virus (VZV) antibodies at 6 years after booster vaccination
Time frame: at 6 years after booster vaccination
Seropositive rate
The seropositive rate of VZV antibodies at 10 years after booster vaccination
Time frame: at 10 years after booster vaccination
GMT of VZV antibody
The GMT of VZV antibodies at 6 years after booster vaccination
Time frame: at 6 years after booster vaccination
GMT of VZV antibody
The GMT of VZV antibodies at 10 years after booster vaccination
Time frame: at 10 years after booster vaccination
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.